Skip to main content

Advertisement

SpringerLink
Log in

Increased of fasting active glucagon-like peptide-1 is associated with insulin resistance in patients with hypertriglyceridemia

  • Original Article
  • Published:
International Journal of Diabetes in Developing Countries Aims and scope Submit manuscript

Abstract

Background

Glucagon-like peptide-1 (GLP-1) is an incretin hormone that facilitates insulin secretion and preserves β cell function. hypertriglyceridemia plays an important role in the pathogenesis of insulin resistance and T2DM. The purpose of this study was to measure fasting active GLP-1 levels in hypertriglyceridemia subjects and analyse the relationship between GLP-1 and insulin resistance.

Methods

We recruited 146 subjects including 38 diabetes patients with hypertriglyceridemia, 33 diabetes patients without hypertriglyceridemia, 35 hypertriglyceridemia subjects, and 40 healthy subjects as the normal control group. Serum fasting active GLP-1 was tested with ELISA in the four groups, and associations with insulin resistance were analysed.

Results

Serum fasting active GLP-1 levels were significantly increased in hypertriglyceridemia subjects with or without T2DM compared with healthy controls, particularly hypertriglyceridemia patients with T2DM (p < 0.01). GLP-1 levels positively correlated with triglyceride (TG) levels, fasting insulin (FINS) levels, and HOMA-IR (p < 0.01). Furthermore, multiple stepwise regression showed that TG levels and HOMA-IR were independently associated with fasting active GLP-1 levels (p < 0.01).

Conclusions

Hypertriglyceridemia was associated with elevated fasting active GLP-1 levels, and a significant association was noted between GLP-1 and HOMA-IR. This finding provides evidence that the increase in GLP-1 may play a compensatory role in the pathogenesis of insulin resistance induced by hypertriglyceridemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Walatara KN, Athiththan LV, Hettiaratchi UK, Perera PR. Effect of demographic status and lifestyle habits on glycaemic levels in apparently healthy subjects: a cross-sectional study. J Diabetes Res. 2016;2016:5240503.

    Article  Google Scholar 

  2. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes. 1992;41:715–22.

    Article  CAS  Google Scholar 

  3. Li YX, Han TT, Liu Y, Zheng S, Zhang Y, Liu W, et al. Insulin resistance caused by lipotoxicity is related to oxidative stress and endoplasmic reticulum stress in LPL gene knockout heterozygous mice. Atherosclerosis. 2015;239:276–82.

    Article  CAS  Google Scholar 

  4. Large V, Arner P. Regulation of lipolysis in humans. Pathophysiological modulation in obesity, diabetes, and hyperlipidaemia. Diabetes Metab. 1998;24:409–18.

    CAS  PubMed  Google Scholar 

  5. Kashyap S, Belfort R, Gastaldelli A, Pratipanawatr T, Berria R, Pratipanawatr W, Mandeep B, et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes. 2003;52:2461–74.

    Article  CAS  Google Scholar 

  6. Wang L, Folsom AR, Zheng ZJ, Pankow JS, Eckfeldt JH, ARIC Study investigators. Plasma fatty acid composition and incidence of diabetes in middle-aged adults: the atherosclerosis risk in communities (ARIC) Study. Am J Clin Nutr. 2003;78:91–8.

    Article  CAS  Google Scholar 

  7. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409–39.

    Article  CAS  Google Scholar 

  8. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev. 1999;20:876–913.

    Article  CAS  Google Scholar 

  9. Friedrichsen BN, Neubauer N, Lee YC, Gram VK, Blume N, Petersen JS, et al. Stimulation of pancreatic beta-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways. J Endocrinol. 2006;188:481–92.

    Article  CAS  Google Scholar 

  10. Holst JJ, Knop FK, Vilsbøll T, Krarup T, Madsbad S. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care. 2011;34(Suppl 2):S251–7.

    Article  CAS  Google Scholar 

  11. Vilsbøll T. On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of type 2diabetes mellitus. Dan Med Bull. 2004;51:364–70.

    PubMed  Google Scholar 

  12. Fukase N, Igarashi M, Takahashi H, Manaka H, Yamatani K, Daimon M, et al. Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients. Diabet Med. 1993;10:44–9.

    Article  CAS  Google Scholar 

  13. Calanna S, Christensen M, Holst JJ, Laferrère B, Gluud LL, Vilsbøll T, Knop FK. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia. 2013;56:965–72.

    Article  CAS  Google Scholar 

  14. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia. 2011;54:10–8.

    Article  CAS  Google Scholar 

  15. Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med. 2005;11:90–4.

    Article  CAS  Google Scholar 

  16. Brubaker PL, Schloos J, Drucker DJ. Regulation of glucagon-like peptide-1 synthesis and secretion in the GLUTag enteroendocrine cell line. Endocrinology. 1998;139:4108–14.

    Article  CAS  Google Scholar 

  17. Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 2012;61:364–71.

    Article  CAS  Google Scholar 

  18. Edfalk S, Steneberg P, Edlund H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes. 2008;57:2280–7.

    Article  CAS  Google Scholar 

  19. Wadden D, Cahill F, Amini P, Randell E, Vasdev S, Yi Y, et al. Circulating glucagon-like peptide-1 increases in response to short-term overfeeding in men. Nutr Metab (Lond). 2013;10:33.

    Article  CAS  Google Scholar 

  20. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes care. 2014;37(Suppl 1):81–90.

    Article  Google Scholar 

  21. Marchesini G, Forlani G, Cerrelli F, Manini R, Natale S, Baraldi L, et al. WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with type 2 diabetes. Diabet Med. 2004;21:383–7.

    Article  CAS  Google Scholar 

  22. Hansen KB, Vilsbøll T, Bagger JI, Holst JJ, Knop FK. Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects. J Clin Endocrinol Metab. 2010;95:3309–17.

    Article  CAS  Google Scholar 

  23. Ryskjaer J, Deacon CF, Carr RD, Krarup T, Madsbad S, Holst J, et al. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. Eur J Endocrinol. 2006;155:485–93.

    Article  CAS  Google Scholar 

  24. Rydgren T, Börjesson A, Carlsson A, Sandler S. Elevated glucagon-like peptide-1 plasma levels, as a possible adaptive response, in diabetic NOD mice. Biochem Biophys Res Commun. 2012;423:583–7.

    Article  CAS  Google Scholar 

  25. Yamaoka-Tojo M, Tojo T, Takahira N, Matsunaga A, Aoyama N, Masuda T, et al. Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease. Cardiovasc Diabetol. 2010;9:17.

    Article  Google Scholar 

  26. Wu P, Yang L, Shen X. The relationship between GPR40 and lipotoxicity of the pancreatic beta-cells as well as the effect of pioglitazone. Biochem Biophys Res Commun. 2010;403:36–9.

    Article  CAS  Google Scholar 

  27. Liu Z, Stanojevic V, Avadhani S, Yano T, Habener JF. Stromal cell-derived factor-1(SDF-1)/chemokine (C-X-Cmotif) receptor4(CXCR4) axis activation induces intra-islet glucagon-like peptide-1 (GLP-1) production and enhances beta cell survival. Diabetologia. 2011;54:2067–76.

    Article  CAS  Google Scholar 

  28. Kappe C, Patrone C, Holst JJ, Zhang Q, Sjöholm A. Metformin protects against lipoapoptosis and enhances GLP-1 secretion from GLP-1-producing cells. J Gastroenterol. 2013;48:322–32.

    Article  CAS  Google Scholar 

  29. Thyssen S, Arany E, Hill DJ. Ontogeny of regeneration of beta-cells in the neonatal rat after treatment with streptozotocin. Endocrinology. 2006;14:2346–56.

    Article  Google Scholar 

  30. Marchetti P, Lupi R, Bugliani M, Kirkpatrick CL, Sebastiani G, Grieco FA, et al. A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia. 2012;55:3262–72.

    Article  CAS  Google Scholar 

  31. Schirra J, Katschinski M, Weidmann C, Schäfer T, Wank U, Arnold R, et al. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest. 1996;97:92–103.

    Article  CAS  Google Scholar 

  32. Krisai P, Aeschbacher S, Schoen T, Bossard M, van der Stouwe JG, Dörig L, et al. Glucagon-like peptide-1 and blood pressure in young and healthy adults from the general population. Hypertension. 2015;65:306–12.

    Article  CAS  Google Scholar 

  33. Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, et al. Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with type 2 diabetes mellitus. Diabet Med. 2000;17:713–9.

    Article  CAS  Google Scholar 

  34. De Luis DA, Gonzalez Sagrado M, Conde R, Aller R, Izaola O. Decreased basal levels of glucagon-like peptide-1 after weight loss in obese subjects. Ann Nutr Metab. 2007;51:134–8.

    Article  Google Scholar 

  35. Herzberg-Schäfer S, Heni M, Stefan N, Häring HU, Fritsche A. Impairment of GLP1-induced insulin secretion: role of genetic background, insulin resistance and hyperglycemia. Diabetes Obes Metab. 2012;14(Suppl 3):85–90.

    Article  Google Scholar 

  36. Sleddering MA, Bakker LE, Janssen LG, Meinders AE, Jazet IM. Higher insulin and glucagon-like peptide-1 (GLP-1) levels in healthy, young South Asians as compared to Caucasians during an oral glucose tolerance test. Metabolism. 2014;63:226–32.

    Article  CAS  Google Scholar 

Download references

Funding

This study was supported by Medical health and Scientific Research Foundation of Shandong Province ((No.2018WS028) and Yantai Science and Technology Project ((No. 2019YD012).

Author information

Author notes

  1. Lujie Zhao and Ying Sun contributed equally to this work.

Authors and Affiliations

  1. Hemodialysis Center, Yantai Yuhuangding Hospital Affiliated To Qingdao University, 20, Yuhuangding East Road, Yantai, Shandong, China

    Lujie Zhao

  2. Department of Endocrinology, Yantai Yuhuangding Hospital Affiliated To Qingdao University, 20, Yuhuangding East Road, Yantai, 264000, Shandong, China

    Ying Sun, Wei Wang, Liang Wang & Chaolin Li

Authors
  1. Lujie Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ying Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Liang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chaolin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chaolin Li.

Ethics declarations

This study was approved by the local ethics committee at Yantai Yuhuangding Hospital and all participants provided the written informed consents. This research conforms to the latest revision of the Declaration of Helsinki.

Ethics approval

The study complied with the principles of the Declaration of Helsinki, and the protocol was approved by the Medical Ethics Committee of Yantai Yuhuangding Hospital, Shandong, China. The purposes and procedures of the study were explained to patients before blood sampling.

Conflict of interest

The authors declare that there are no conflicts of interest.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhao, L., Sun, Y., Wang, W. et al. Increased of fasting active glucagon-like peptide-1 is associated with insulin resistance in patients with hypertriglyceridemia. Int J Diabetes Dev Ctries 42, 211–217 (2022). https://doi.org/10.1007/s13410-021-00971-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13410-021-00971-3

Keywords

Search

Navigation